Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEE™ (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age ...

STATEN ISLAND, N.Y. — In the “Big Heart” department, Mike DiLeo, executive chef at Max’s Esca, played host to “Savor the ...

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEEtm (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age ...

In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with ...

Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced ...

When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...

Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price ...

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ...

Pillar Biosciences, the leader in Decision Medicinetm, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricing determination for oncoReveal CDx. Following its ...

FDA approves dosing in Sarepta's ENDEAVOR Cohort 8 to test sirolimus with Elevidys in non-ambulant Duchenne patients, ...

The beauty of the DNA code is that organisms interpret it unambiguously. Each three-letter nucleotide sequence, or codon, in ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive ...